logo

Caladrius Biosciences, Inc. (CLBS)



Trade CLBS now with
  Date
  Headline
11/8/2018 8:32:16 AM Caladrius Biosciences Appoints Cynthia Schwalm To Board
6/19/2018 8:04:25 AM Caladrius Gets FDA Regenerative Medicine Advanced Therapy Designation For CD34+ Cell Therapy For Refractory Angina
5/10/2018 4:09:52 PM Caladrius Biosciences Q1 Net Loss From Cont Ops $5.0 Mln Or $0.52 Per Share
4/10/2018 8:04:22 AM Caladrius Biosciences Receives SAKIGAKE Expedited Review Designation In Japan For CLBS12 For Critical Limb Ischemia
3/22/2018 4:08:37 PM Caladrius Biosciences Q4 Loss/share $0.29 Vs. Loss $0.73 Year Ago
3/13/2018 8:04:54 AM Caladrius Biosciences Doses First Patient With CLBS12 In Phase 2 Critical Limb Ischemia Trial In Japan
3/6/2018 8:05:34 AM Caladrius Acquires License To Late Stage CD34+ Cell Therapy Program For Treatment Of Refractory Angina